Insider Buying: Insulet (NASDAQ:PODD) Director Acquires 2,790 Shares of Stock

Insulet Corporation (NASDAQ:PODD) Director Timothy Stonesifer acquired 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Insulet Stock Up 2.2%

Shares of NASDAQ:PODD traded up $3.11 during trading hours on Thursday, reaching $146.41. The stock had a trading volume of 1,409,969 shares, compared to its average volume of 1,181,413. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88. The firm’s 50 day moving average is $178.57 and its 200-day moving average is $240.82. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock has a market capitalization of $10.14 billion, a price-to-earnings ratio of 34.05, a P/E/G ratio of 1.12 and a beta of 1.13.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period in the prior year, the firm posted $1.02 EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts predict that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

Several institutional investors have recently bought and sold shares of PODD. Larson Financial Group LLC grew its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the fourth quarter worth $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the fourth quarter worth $28,000. DV Equities LLC acquired a new position in shares of Insulet during the fourth quarter worth $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet during the fourth quarter worth $29,000.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PODD shares. Piper Sandler dropped their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Stifel Nicolaus lowered their target price on shares of Insulet from $350.00 to $250.00 in a report on Thursday, May 7th. Truist Financial lowered their target price on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Jefferies Financial Group lowered their target price on shares of Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Finally, TD Cowen lowered their target price on shares of Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a report on Monday. Twenty-one analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average price target of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.